| 1 | Variations in Risk Factors across Different Periods of Stroke Recurrence |
|----|---|
| 2 | |
| 3 | Sang-Hun Lee, MD, PhD; Jin-Man Jung, MD, PhD; Jae-Chan Ryu, MD; Moon-Ho Park, MD, |
| 4 | PhD |
| 5 | Department of Neurology, Korea University Ansan Hospital, Korea University College of |
| 6 | Medicine, Ansan, Republic of Korea |
| 7 | Correspondence to: |
| 8 | Moon-Ho Park, MD, PhD |
| 9 | Department of Neurology, Korea University Ansan Hospital, Korea University College of |
| 10 | Medicine, Gojan 1-Dong, Danwon-Gu, Ansan-si, Gyeonggi-do 152-703, Republic of Korea |
| 11 | Tel: +82-31-412-5150, FAX: +82-31-412-5154 |
| 12 | E-mail: parkmuno@korea.ac.kr |
| 13 | Short title: Stroke recurrence and risk factors |
| 14 | Number of characters in the title: 72 |
| 15 | Number of words in the manuscript: 3004 |
| 16 | Number of figures: 3 |
| 17 | Number of table: 1 |
| 18 | Number of supplementary table: 1 |
| 19 | |

20

21 Abstract

Background and Purpose: Accurately discerning periods of heightened risk of stroke recurrence and managing modifiable risk factors are essential for minimizing overall recurrence risk. This study identified differences in the timing of stroke recurrence based on risk factors and patient characteristics to develop strategies for reducing recurrence in clinical practice.

27 **Methods:** We retrospectively selected patients with ischemic stroke or transient ischemic 28 attack at the Korea University Ansan Hospital Stroke Center between March 2014 and 29 December 2021 using the prospective institutional database of the Korea University Stroke 30 Registry. We collected demographic, clinical, and stroke data and categorized participants by 31 recurrence timing (early within 3 months or late after 3 months). Using multinomial logistic 32 regression analysis, we examined variables associated with early and late recurrent strokes.

Results: The analysis included 3,646 patients, of whom 255 experienced a recurrent stroke and 3,391 experienced their first stroke. Multinomial logistic regression analysis revealed significant associations between early recurrent stroke and diabetes mellitus (OR 1.98, 95% CI 1.25–3.15), other determined etiologies in TOAST classification (OR 3.00, 95% CI 1.37– 6.61), and white matter changes (OR 1.97, 95% CI 1.17–3.33). Late recurrent stroke showed a significant correlation with transient ischemic attack (TIA) (OR 2.95, 95% CI 1.52–5.71) and cerebral microbleeds (OR 2.22, 95% CI 1.32–3.75).

40 **Conclusion:** Our study emphasizes substantial differences in factors contributing to stroke 41 recurrence based on timing. Managing the risk of recurrence in clinical practice necessitates 42 accurate identification of heightened risk periods and rigorous control of modifiable risk 43 factors.

44 Keywords: stroke recurrence, early recurrent stroke, late recurrent stroke

45 Introduction

Stroke is a disabling disease that causes high mortality rates and a significant decline in quality of life worldwide (1-3). Stroke exhibits a frequent recurrence compared to other diseases (4,5). Recurrent stroke causes more serious neurological damage, is more difficult to treat, and carries a higher risk of death, readmission, and long-term disability than the first stroke. Therefore, secondary prevention after the first stroke is critical to reducing stroke recurrence (6).

Understanding recurrent stroke is important. Previous studies have investigated 52 important variables for stroke recurrence, including age, diabetes, smoking, arterial 53 hypertension, hyperlipidemia, peripheral arterial disease, hypercoagulable states, depression, 54 55 and the National Institutes of Health Stroke Scale (NIHSS) score status (7-10). The cumulative incidence of stroke recurrence in the first 5 years is 16-30% (11-13). However, 56 57 the stroke recurrence rate varies significantly over time, particularly after the initial stroke. 58 The timing of recurrence shows significant heterogeneity depending on the risk factors (3). The risk of recurrence ranged from 3.54 to 24.5% in the first year after the first stroke (14,15); 59 the 2-year recurrence rate was approximately 30% (6); and in the following 5 years, it was in 60 61 the range of 9.4% to 22.90% (16,17).

Precision in identifying the heightened risk of stroke recurrence and managing modifiable risk factors is crucial for minimizing the overall recurrence risk. The existing literature has overlooked early recurrence in the subacute phase, which occurs within 3 months after cerebral infarction. Consequently, our study aimed to address this research gap by identifying the risk factors and characteristics associated with early recurrence, particularly within the initial 3-month period. These findings provide valuable insights for clinical practice, aiding in the reduction of early recurrence rates.

71 Methods

72 Participants

This is a prospective institutional database from the Korea University Stroke Registry. 73 74 The design of the database has been described in detail previously (18). Briefly, we 75 retrospectively selected consecutive patients with ischemic stroke or transient ischemic attack (TIA) (diagnosed by a neurologist within 30 days of the event) who were admitted to the 76 77 stroke center of Korea University Ansan Hospital between March 2014 and December 2021 due to neurological problems. Patients with hemorrhagic strokes were excluded from the 78 79 study. (Figure 1) Stroke was defined as focal clinical signs of central nervous system dysfunction of vascular origin that lasted for at least 24 h according to the World Health 80 Organization (Geneva) criteria. TIA was defined as losing cerebral or ocular function for less 81 82 than 24 h. The recurrence of cerebral infarction was determined by neurological symptoms 83 and ischemic changes detected on imaging tests.

Information on demographics, clinical evaluations, neurological examinations, stroke 84 85 characteristics, and outcomes was obtained. The diagnosis required brain computed tomography (CT) and/or magnetic resonance imaging (MRI) to exclude hemorrhage and 86 87 other causes of symptoms. Each patient required at least one vascular imaging scan, including conventional angiography, arterial imaging using MR angiography, CT angiography, or 88 duplex ultrasound imaging. Standard systemic investigations were performed for every 89 90 patient, including routine laboratory tests, chest radiography, and 12-lead electrocardiography. Routine laboratory tests included a complete blood count, electrolyte, glucose, renal function, 91 liver function, lipid profile, and homocysteine levels. Transcranial Doppler, carotid duplex 92 93 sonography, transthoracic echocardiography, transesophageal echocardiography, and 24-h Holter electrocardiography monitoring were performed in selected patients. This study was 94 approved by the Institutional Review Board of Korea University Ansan Hospital (approval no. 95

96 AS0213). Informed consent was not required owing to the retrospective design of the study.

97

98 <u>Clinical and Laboratory Assessment</u>

99 For demographics and comorbidities, age at admission was categorized into three groups (<60, 60–74, and \geq 75 years). Body mass index (BMI) was calculated as weight in 100 kilograms divided by height in meters squared (kg/m^2) and was categorized into four groups 101 (underweight, <18.5; normal weight, 18.5–22.9; overweight, 23.0–24.9; obese, \geq 25.0) by 102 modified previous criteria (19). The weight and height required for BMI measurements were 103 104 measured within 24 h of admission. The smoking status was classified as current smoker or nonsmoker. Hypertension was defined as a systolic blood pressure of at least 140 mmHg, a 105 106 diastolic blood pressure of at least 90 mmHg, or the presence of hypertension when patients 107 were previously diagnosed or were receiving antihypertensive medication. Diabetes mellitus 108 was defined as a fasting serum glucose level of ≥ 126 mg/dL, a non-fasting serum glucose level of $\geq 200 \text{ mg/dL}$, a hemoglobin A1c level of $\geq 6.5\%$, or a history of insulin therapy and/or 109 110 oral hypoglycemic drugs. Dyslipidemia was defined as a total cholesterol level of ≥ 200 mg/dL. Blood samples were obtained from all participants after at least 8 h of fasting on the 111 morning of admission. Stroke is associated with abnormal biochemical parameters, including 112 anemia (20), leukocytosis (21), elevated high-sensitivity C-reactive protein (CRP) levels (21), 113 114 high homocysteine levels (22), and reduced kidney function (23). In this study, these 115 biochemical cut-off points were used to define and categorize abnormal levels: anemia was defined as hemoglobin <12 g/dL in females and <13 g/dL in males; leukocytosis was defined 116 as a white blood count of >12,000/ μ L; hyperhomocysteinemia >15 μ mol/L; CRP elevation >2 117 118 mg/L; and abnormal kidney function as estimated glomerular filtration rate <60 mL/min per 1.73 m^2 . 119



Atrial fibrillation (AF) was defined as persistent atrial arrhythmia with irregular R-R intervals and no clear repetitive P waves and was diagnosed with an electrocardiogram, 24-h Holter, or continuous electrocardiogram monitoring during hospitalization.

124 White matter changes (WMCs) in the hemisphere contralateral to the area affected by the acute stroke were assessed using the proposed visual rating scale (24,25). If the WMCs were 125 higher on one side, the rating was based on the less involved or uninvolved side with the 126 127 assumption of symmetry. In this study, the WMCs rating was modified using a dichotomous method (WMCs, grade 3 vs. no WMCS, grades 1-2). Cerebral microbleeds (CMBs) were 128 129 assessed as rounded or ovoid hypointense lesions on a T2-GRE-weighted sequence of MRI (26). CMBs measured 10 mm or less in diameter and were surrounded by brain parenchyma 130 over at least half the circumference of the lesion. The severity of neurological deficits at 131 132 admission was rated using the National Institutes of Health Stroke Scale (NIHSS) score (27) on the day of admission, defined as poor initial NIHSS (NIHSS score \geq 5), which was 133 evaluated by the certified neurologists who were blind to this study. 134

135 For subtypes of stroke, ischemic stroke was classified according to the Trial of Org 10172 in the Acute Stroke Treatment (TOAST) classification system (28): large artery disease 136 (LAD), cardioembolism (CE), small vessel occlusion (SVO), stroke of other determined 137 etiology (OD), and stroke of undetermined etiology (UD). The UD category included three 138 heterogeneous groups: "two or more causes," "negative evaluation," and "incomplete 139 140 evaluation." Recurrent stroke was defined as a new neurological deficit or deterioration of the previous deficit and fit the definitions for ischemic stroke, or TIA. Recurrent stroke was 141 classified according to the recurrent interval as early recurrent stroke (≤ 3 months) or late 142 143 recurrent stroke (>3 months). The extent of the diagnostic workup, stroke, and TIA were determined primarily by the stroke neurologists in charge of the patients, and the types of 144 stroke and TIA were confirmed at a monthly stroke registry meeting. 145

146

147 <u>Statistical Analysis</u>

All participants were categorized according to stroke recurrence (recurrent stroke group and first-ever stroke group), and the recurrent stroke group was further subcategorized into early and late recurrent stroke groups. Categorical variables are described in terms of frequencies and percentages. Differences in characteristics among groups were analyzed using Pearson's chi-squared (χ^2) test or Fisher's exact test, as applicable. A pairwise *z*-test with the Bonferroni correction was used to determine the significance of the contribution of each subgroup of variables.

To identify potential predictors of recurrent stroke, we selected variables with P < 0.2155 in a bivariable analysis. We used a modified Nightingale-Rose diagram to show the 156 157 distribution of potential predictors of recurrent stroke. These potential variables of recurrent stroke were used to generate a predictive model for each recurrent stroke by multivariable 158 binary and multinomial logistic regression models using bootstrapping methods with a 159 160 statistically significant association at P < 0.05 compared to those of first-ever stroke. Goodness-to-fit and pseudo-R square statistics were used to evaluate the model fit and 161 predictive strength. The final models were used to calculate the adjusted odds ratios (ORs) 162 and 95% confidence intervals (CIs). 163

164 Statistical significance was declared when the two-tailed *P*-value was <0.05. 165 Statistical analyses were performed using R version 4.2.1 software (R Foundation for 166 Statistical Computing, Vienna, Austria) and SPSS (version 20.0; IBM SPSS, Chicago, IL, 167 USA).

168

169 **Results**

170

Between March 2014 and December 2021, 4,508 individuals with ischemic stroke or

171 transient ischemic attack (TIA) were admitted to the Stroke Center at Korea University Ansan Hospital. Of these, 862 patients were excluded from the final analysis, comprising 709 172 patients who refused the omission of tests for the stroke registry and 153 patients who were 173 174 lost during the evaluation period for stroke recurrence. Consequently, the final analysis included 3,646 patients, of whom 255 experienced recurrent strokes and 3,391 had their first 175 stroke. (Figure 1) 176

177

Differential Clinical Characteristics in Recurrent Stroke Versus First-Ever 178

179 Table 1 outlines the demographic and clinical features of the participants according to the occurrence of stroke recurrence. The recurrent stroke patient group had a significantly 180 higher proportion of men than the first-ever stroke group (71.4% vs. 60.4%, p = 0.001). 181 Variations in BMI across categories, such as normal, underweight, overweight, and obese, 182 showed that patients with the underweight category (BMI 18.5–22.9) showed a significantly 183 higher rate of recurrent stroke (9.1% vs. 4.4%, p = 0.005). 184

185 Concerning stroke risk factors, higher recurrence rates were observed in individuals with hypertension, diabetes mellitus, and congestive heart failure. Stratifying participants 186 based on stroke subtype according to the TOAST (Trial of Org. 10172 in Acute Stroke 187 Treatment) classification revealed a significantly lower recurrence rate in cases of small 188 vessel occlusion (SVO) (14.9% vs. 24.8%, p = 0.005). 189

190 Laboratory findings indicated a higher prevalence of anemia, elevated CRP levels exceeding 2 mg/dL, and a low estimated glomerular filtration rate (eGFR) in recurrent 191 cerebral infarctions. In terms of radiological findings, white matter changes and cerebral 192 193 microbleeds were associated with recurrent strokes.

194

Differences in Clinical Characteristics among Early Recurrent Stroke, Rate Recurrent Stroke, 195

196 *and First-Ever Stroke*

Figure 2. summarizes the analysis of the differences between the initial recurrent stroke, recurrent stroke rate, and first stroke using a diagram. For variables such as male sex, diabetes mellitus, TOAST classification, anemia, and cerebral microbleeds, patients with early and late recurrent stroke showed similar patterns of significant differences when compared with patients with first-ever stroke.

Regarding BMI (p = 0.002), congestive heart failure (p = 0.024), leukocytosis (p = 0.029), and white matter changes (p < 0.001), significant differences were observed in comparison to first-ever stroke patients only in the early recurrent stroke group. However, regarding dyslipidemia (p = 0.047), significant differences in patients with first-ever stroke were observed only in the late recurrent stroke group.

A comparison of early and late recurrent strokes showed significant differences in TOAST classification and CRP levels. This is expressed in detail in Supplementary Table 1.

209

210 <u>Multivariable Logistic Regression Analysis of Predictive Factors for Early and Late</u> 211 <u>Recurrent Stroke</u>

A multinomial logistic regression analysis was used to analyze the early and late recurrent stroke variables. (Figure 3) For overall recurrent stroke, male sex (OR 2.05, 95% CI 1.45–2.88), hypertension (OR 1.54, 95% CI 1.06–2.22), diabetes mellitus (OR 1.59, 95% CI 1.15–2.18), other determined etiologies in TOAST classification (OR 1.98, 95% CI 1.04– 3.78), TIA (OR 2.01, 95% CI 1.18–3.43), anemia (OR 3.96, 95% CI 2.81–5.57), white matter changes (OR 1.62, 95% CI 1.08–2.44), and cerebral microbleeds (OR 1.88, 95% CI 1.29– 2.72) showed significant results.

In the context of early recurrent stroke, significant associations were observed for diabetes mellitus (OR 1.98, 95% CI 1.25–3.15), other determined etiology in TOAST

classification (OR 3.00, 95% CI 1.37–6.61), and white matter changes (OR 1.97, 95% CI 1.17–3.33). Conversely, in the case of late recurrent stroke, a significant correlation was
noted with the transient ischemic attack (TIA) (OR 2.95, 95% CI 1.52–5.71) and cerebral
microbleeds (OR 2.22, 95% CI 1.32–3.75). Additionally, for both early and late recurrent
stroke, significant associations were observed with male sex (OR 1.98, 95% CI 1.25–3.15;
OR 2.14, 95% CI 1.32–3.48, respectively) and anemia (OR 4.53, 95% CI 2.84–7.20; OR 3.40,
95% CI 2.10–5.51, respectively).

228

229 Discussion

In this study, we focused on understanding the factors influencing stroke recurrence and distinguishing patients experiencing a recurrent stroke from those who experienced a firstever stroke. Given the dynamic nature of stroke recurrence, we anticipated variations in causative factors over time. Consequently, we categorized our analysis into early and late periods based on a 3-month timeframe.

Our findings indicate that certain factors are closely associated with stroke recurrence within the first 3 months. Patients with diabetes mellitus, other determined etiologies according to the TOAST classification, and white matter changes were particularly prone to early recurrence. By contrast, individuals with TIA and cerebral microbleeds exhibited a higher likelihood of delayed relapse. Regardless of the timing, male sex and anemia were identified as consistent risk factors for recurrence.

Our investigation aligns with previous studies that explored stroke recurrence. Lee et al. discovered that the risk of 1-year stroke recurrence was significantly elevated in men, older adults, and those with a history of ischemic stroke (29). A meta-analysis by Zheng et al. suggested that hypertension, diabetes, atrial fibrillation, and coronary heart disease are associated with a heightened risk of stroke recurrence (30). In a study by Hillen et al.,

diabetes and atrial fibrillation emerged as significant contributors to outcomes in the first year 246 after the index stroke (31). These risk factors are associated with stroke recurrence, with 247 significant differences. Reviewing multiple prior studies, the most firmly established risk 248 249 factors linked to stroke recurrence were diabetes and atrial fibrillation (32-35). This is consistent with the current research showing that diabetes is a crucial factor. Regarding atrial 250 fibrillation, our study suggests a tendency for a higher prevalence in patients experiencing 251 252 recurrent cerebral infarction. However, the results no longer reached statistical significance. This observation could be attributed to the widespread clinical use of NOACs and the 253 254 heightened early atrial fibrillation detection rate facilitated by tools such as injectable cardiac 255 monitors and long-term Continuous Ambulatory ECG Monitors.

Previous research results on hypertension were more heterogeneous, and several studies reported that hypertension was associated with the highest risk of stroke recurrence. However, few studies reported a significant association with stroke recurrence, which may be related to different criteria and methods for measuring hypertension and issues with antihypertensive management (9,31,32,35,36). Although this study demonstrated a correlation with overall stroke recurrence, no significant correlation was observed with early recurrent stroke.

In our study, a high initial recurrence rate was observed in the category of "other 263 determined etiology" in the TOAST classification, consistent with findings from previous 264 265 research. Specifically, within this classification, the majority of patients exhibited dissection, Moyamoya disease, and cancer-related coagulopathy, which is consistent with past studies 266 that have identified these conditions as being associated with elevated recurrence rates. For 267 268 instance, Christian Weimar et al. highlighted the heightened risk of early recurrent stroke following acute ischemic stroke, or TIA, attributed to carotid artery dissection (37). Moreover, 269 a study by Chiu et al. indicated that Moyamoya disease entails a high risk of stroke 270

271 recurrence, with an 18% recurrence rate within the first year after diagnosis, decreasing to approximately 5% over the subsequent 5 years (38). This trend may be influenced by the 272 gradual development of angiogenesis and collaterals following the initial cerebral infarction. 273 274 The recurrence rate was higher in patients with cancer-related strokes than in patients with 275 inactive cancer or controls. The estimated one-year stroke recurrence rate in patients with cancer and embolic stroke of undetermined source (ESUS) ranges from 14% to 29%, which 276 277 is approximately three times higher than that in ESUS patients without cancer (35). White matter changes (WMCs) indicate stroke recurrence up to 5 years after the first ischemic 278 279 stroke. This shows that white matter change (WMC) can be considered an SVD marker that 280 summarizes the impact of several classical risk factors on small-vessel brain networks (39). We observed that WMC had a particularly strong impact on early recurrent strokes. 281 282 Conversely, the association between TIA and late recurrent stroke can be attributed to the 283 possibility that symptoms are not observed for an extended duration during the treatment process. The risk factors are effectively managed, and clinicians may opt to discontinue 284 285 antithrombotic drugs in clinical practice. Considerably, the risk of recurrence in these cases being detected after a long period of time is higher compared to patients with cerebral 286 infarction who consistently adhere to antithrombotic therapy. 287

Our study has several limitations. First, this was a single-hospital investigation. 288 Inherent in utilizing clinical registry data is a potential bias in patient selection, recording 289 290 practices, data completeness, and outcome assessment. Therefore, generalizing the findings of this study may be challenging. To bolster the robustness of these results, it is imperative to 291 validate them through prospective multicenter studies with larger sample sizes. Second, a 292 293 challenge in examining stroke recurrence is the difficulty of identifying such recurrences, particularly if they manifest immediately after the index stroke. Detecting new neurological 294 signs in unconscious, paralyzed, or bedridden patients with a Modified Rankin Scale (mRS) 295

score of 4 or higher is markedly more challenging than in individuals who have recovered. Third, while we categorized stroke recurrence into early (within three months) and late (beyond three months) groups, a more nuanced classification of the late recurrence group could have yielded more detailed insights. Lastly, during the initial 3 months, the loss of follow-up was minimal. However, beyond this period, patients exhibited increased loss of follow-up, potentially introducing bias to our findings.

In conclusion, our study underscores the substantial differences in the causative factors of stroke recurrence, contingent on the timing of recurrence. Effectively mitigating the risk of recurrence in clinical practice necessitates accurately identifying periods when the risk of stroke recurrence is heightened, coupled with stringent control of modifiable risk factors.

306

307 Acknowledgments: None.

Sources of funding: This work was supported by the National Research Foundation of Korea
(NRF) grant funded by the Korea Government (Ministry of Science and ICT) (RS-2023-

310 00246890).

311 Conflict of Interest

312 The authors have no financial conflicts of interest.

313 Author contributions:

314 Dr. SH Lee contributed to the study conception and design, data analysis, acquisition of

- 315 clinical and imaging data, statistical analysis, and manuscript drafting and revision.
- 316 Dr. MH Park contributed to the study conception and design, analysis, and interpretation of
- the imaging and clinical data, manuscript drafting and revision, and study supervision.
- 318 Dr. JM Jung contributed to the data analysis and manuscript revision.

319 Dr. JC Ryu contributed to the study conception and data statistical analysis.

320

- 322 **References**
- Feigin VL, Norrving B, Mensah GA. Global burden of stroke. *Circulation Research*.
 2017;120:439–448.
- Mahesh PKB, Gunathunga MW, Jayasinghe S, Arnold SM, Liyanage SN. Factors
 influencing pre-stroke and post-stroke quality of life among stroke survivors in a
 lower middle-income country. *Neurological Sciences*. 2018;39:287–295.
- Lin B, Zhang Z, Mei Y, Wang C, Xu H, Liu L, Wang W. Cumulative risk of stroke
 recurrence over the last 10 years: A systematic review and meta-analysis.
 Neurological Sciences. 2021;42:61–71.
- Han J, Mao W, Ni J, Wu Y, Liu J, Bai L, Shi M, Tu J, Ning X, Wang J. Rate and
 determinants of recurrence at 1 year and 5 years after stroke in a low-income
 population in rural china. *Frontiers in Neurology*. 2020;11:2.
- Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in china: huge burden,
 significant workload, and a national priority. *Stroke*. 2011;42:3651-3654.
- 336 6. Zhuo Y, Wu J, Qu Y, Yu H, Huang X, Zee B, Lee J, Yang Z. Clinical risk factors
 337 associated with recurrence of ischemic stroke within two years: A cohort study.
 338 *Medicine (Baltimore)*. 2020;99:e20830.
- 339 7. Modrego PJ, Mainar R, Turull L. Recurrence and survival after first-ever stroke in the
 area of bajo Aragon, Spain. A prospective cohort study. *Journal of the Neurological*341 *Sciences*. 2004;224:49–55.
- 342 8. Lee AH, Somerford PJ, Yau KK. Risk factors for ischaemic stroke recurrence after

343 hospitalisation. *Medical Journal of Australia*. 2004;181:244–246.

- Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence
 after hospitalized cerebral infarction in an urban community: the northern manhattan
 stroke study. *Neurology*. 1994;44:626–634.
- Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence:
 predictors, severity, and prognosis. The Copenhagen stroke study. *Neurology*.
 1997;48:891–895.
- Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU.
 Epidemiology of ischemic stroke subtypes according to toast criteria: incidence,
 recurrence, and long-term survival in ischemic stroke subtypes: A population-based
 study. *Stroke*. 2001;32:2735–2740.
- Mohan KM, Crichton SL, Grieve AP, Rudd AG, Wolfe CD, Heuschmann PU.
 Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke:
 the south london stroke register. *Journal of Neurology, Neurosurgery, and Psychiatry.*2009;80:1012–1018.
- Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve
 AP. Risk and cumulative risk of stroke recurrence: A systematic review and metaanalysis. *Stroke*. 2011;42:1489–1494.
- 14. Pu YH, Zou XY, Wang YL, Pan YS, Xiang XL, Soo AX, Leung HK, Zhao XQ, Wang
 CX, Wong JX, et al. Difference of one year death and stroke recurrence in ischemic
 stroke patients with anterior and posterior circulation intracranial atherosclerosis. *Zhonghua Yi Xue Za Zhi.* 2018;98:502–507.
- Kono Y, Yamada S, Kamisaka K, Araki A, Fujioka Y, Yasui K, Hasegawa Y, Koike Y.
 Recurrence risk after noncardioembolic mild ischemic stroke in a Japanese population. *Cerebrovascular Diseases*. 2011;31:365–372.

- Putaala J, Haapaniemi E, Metso AJ, Metso TM, Artto V, Kaste M, Tatlisumak T.
 Recurrent ischemic events in young adults after first-ever ischemic stroke. *Annals of Neurology*. 2010;68:661–671.
- 17. Kumral E, Güllüoğlu H, Alakbarova N, Karaman B, Deveci EE, Bayramov A,
 Evyapan D, Gökçay F, Orman M. Association of leukoaraiosis with stroke recurrence
 within 5 years after initial stroke. *Journal of Stroke and Cerebrovascular Diseases*.
 2015;24:573–582.
- 18. Lee SH, Jung JM, Park MH. Obesity paradox and stroke outcomes according to stroke
 subtype: A propensity score-matched analysis. *International Journal of Obesity*.
 2023;47:669–676.
- World Health Organization. Regional office for the western pacific. The asia-pacific
 perspective: redefining obesity and its treatment. Sydney: Health Communications
 Australia; 2000.
- 20. Li Z, Zhou T, Li Y, Chen P, Chen L. Anemia increases the mortality risk in patients
 with stroke: A meta-analysis of cohort studies. *Scientific Reports*. 2016;6:26636.
- 21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M,
- Fadl YY, Fortmann SP, Hong Y, Myers GL, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003;107:499–511.
- Jung JM, Kwon DY, Han C, Jo I, Jo SA, Park MH. Increased carotid intima-media
 thickness and plasma homocysteine levels predict cardiovascular and all-cause death:
 A population-based cohort study. *European Neurology*. 2013;70:1–5.
- 391 23. Kelly DM, Ademi Z, Doehner W, Lip GYH, Mark P, Toyoda K, Wong CX, Sarnak M,
- 392 Cheung M, Herzog CA, et al. Chronic kidney disease and cerebrovascular disease:

consensus and guidance from a kdigo controversies conference. *Stroke*. 2021;52:e328e346.

- Park JH, Heo SH, Lee MH, Kwon HS, Kwon SU, Lee JS, PICASSO investigators.
 White matter hyperintensities and recurrent stroke risk in patients with stroke with
 small-vessel disease. *European Journal of Neurology*. 2019;26:911–918.
- Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, Chabriat H,
 Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, et al. Impact of age-related cerebral
 white matter changes on the transition to disability -- the Ladis study: rationale,
 design and methodology. *Neuroepidemiology*. 2005;24:51–62.
- 402 26. Romero JR, Beiser A, Himali JJ, Shoamanesh A, DeCarli C, Seshadri S. Cerebral
 403 microbleeds and risk of incident dementia: the Framingham heart study. *Neurobiology*404 *of Aging*. 2017;54:94–99.
- Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J,
 Marler J. Improved reliability of the nih stroke scale using video training. NINDS tpa
 stroke study group. *Stroke*. 1994;25:2220–2226.
- Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE.
 Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter
 clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. *Stroke*.
 1993:24:35–41.
- Lee JD, Hu YH, Lee M, Huang YC, Kuo YW, Lee TH. High risk of one-year stroke
 recurrence in patients with younger age and prior history of ischemic stroke. *Current Neurovascular Research.* 2019;16:250–257.
- 30. Zheng S, Yao B. Impact of risk factors for recurrence after the first ischemic stroke in
 adults: A systematic review and meta-analysis. *Journal of Clinical Neuroscience*.
 2019;60:24–30.

- 418 31. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD, South London
 419 Stroke Register. Cause of stroke recurrence is multifactorial: patterns, risk factors, and
 420 outcomes of stroke recurrence in the south london stroke register. *Stroke*.
 421 2003;34:1457–1463.
- 422 32. Hier DB, Foulkes MA, Swiontoniowski M, Sacco RL, Gorelick PB, Mohr JP, Price
 423 TR, Wolf PA. Stroke recurrence within 2 years after ischemic infarction. *Stroke*.
 424 1991;22:155–161.
- 425 33. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, Stewart426 Wynne EG. Long-term risk of first recurrent stroke in the perth community stroke
 427 study. *Stroke*. 1998;29:2491–2500.
- 34. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of
 recurrent stroke after a first-ever stroke. The Oxfordshire community stroke project. *Stroke*. 1994;25:333–337.
- 431 35. Lai SM, Alter M, Friday G, Sobel E. A multifactorial analysis of risk factors for
 432 recurrence of ischemic stroke. *Stroke*. 1994;25:958–962.
- 433 36. Hillen T, Dundas R, Lawrence E, Stewart JA, Rudd AG, Wolfe CD. Antithrombotic
 434 and antihypertensive management 3 months after ischemic stroke: A prospective study
 435 in an inner city population. *Stroke*. 2000;31:469–475.
- Weimar C, Kraywinkel K, Hagemeister C, Haass A, Katsarava Z, Brunner F,
 Haverkamp C, Schmid E, Diener HC, German Stroke Study Collaboration. Recurrent
 stroke after cervical artery dissection. *Journal of Neurology, Neurosurgery, and Psychiatry*. 2010;81:869–873.
- 440 38. Chiu D, Shedden P, Bratina P, Grotta JC. Clinical features of Moyamoya disease in
 441 the united states. *Stroke*. 1998;29:1347–1351.
- 442 39. Melkas S, Sibolt G, Oksala NK, Putaala J, Pohjasvaara T, Kaste M, Karhunen PJ,

Erkinjuntti T. Extensive white matter changes predict stroke recurrence up to 5 years 443

after a first-ever ischemic stroke. Cerebrovascular Diseases. 2012;34:191-198. 444

| Variables | Recurrent stroke (n = 255) | First-ever stroke $(n = 3,391)$ | <i>P</i> value |
|--------------------------------------|-------------------------------|---------------------------------|----------------|
| | | | |
| age, yrs | | | 0.952 |
| <60 | 86 (33.7%) | 1,167 (34.4%) | >0.999* |
| 61–74 | 91 (35.7%) | 1,178 (34.7%) | >0.999* |
| ≥75 | 78 (30.6%) | 1,046 (30.8%) | >0.999* |
| sex, male | 182 (71.4%) | 2,049 (60.4%) | 0.001 |
| body mass index (kg/m ²) | | | 0.002 |
| normal (<18.5) | 90 (35.4%) | 1,125 (33.3%) | >0.999* |
| underweight (18.5–22.9) | 23 (9.1%) | 147 (4.4%) | 0.005^{*} |
| overweight (23.0–24.9) | 61 (24.0%) | 784 (23.2%) | >0.999* |
| obese (25.0–29.9) | 80 (31.5%) | 1,321 (39.1%) | 0.129* |
| current smoking | 60 (23.5%) | 899 (26.5%) | 0.338^{*} |
| stroke risk factors | | | |
| hypertension | 176 (69.0%) | 2,076 (61.2%) | 0.013 |
| diabetes mellitus | 123 (48.2%) | 1,120 (33.0%) | < 0.001 |
| congestive heart failure | 15 (5.9%) | 107 (3.2%) | 0.028 |
| atrial fibrillation | 51 (20.0%) | 577 (17.0%) | 0.229 |
| dyslipidemia | 118 (59.6%) | 2,102 (63.3%) | 0.290 |
| TOAST | | | 0.003 |
| LAD | 50 (19.6%) | 621 (18.3%) | >0.999* |
| CE | 45 (17.6%) | 569 (16.8%) | >0.999* |
| SVO | 38 (14.9%) | 840 (24.8%) | 0.005^{*} |
| OD | 21 (8.2%) | 183 (5.4%) | 0.686^{*} |
| UD | 52 (20.4%) | 702 (20.7%) | >0.999* |
| TIA | 49 (19.2%) | 476 (14.0%) | 0.277^{*} |
| laboratory, radiological findings | | | |
| anemia | 133 (53.0%) | 704 (20.8%) | < 0.001 |
| leukocytosis | 34 (13.5%) | 341 (10.1%) | 0.085 |
| elevated CRP | 35 (18.6%) | 379 (12.2%) | 0.012 |
| Hyperhomocysteinemia | 32 (21.1%) | 625 (20.0%) | 0.756 |
| low eGFR | 65 (25.7%) | 538 (15.9%) | < 0.001 |
| white matter changes | 52 (20.4%) | 425 (12.5%) | 0.001 |

Table 1. Clinical characteristics according to stroke recurrence 446

| cerebral microbleeds | 61 (23.9%) | 548 (16.2%) | 0.002 |
|----------------------|------------|---------------|-------|
| clinical finding | | | |
| poor initial NIHSS | 73 (30.3%) | 1,046 (31.8%) | 0.667 |

447 Data are expressed as actual counts (percentages) unless otherwise specified.

448 As a few variables were missing, the number of available data points was 3631 for BMI, 3518 for 449 dyslipidemia, 3635 for anemia, 3635 for leukocytosis, 3307 for CRP, 3282 for homocysteine, 3639 for

450 eGFR, and 3530 for poor initial NIHSS.

P values without asterisks (*) were calculated from the two-way chi-square test between patients with recurrent strokes and those with first-ever strokes. P values with asterisks (*) are calculated from a pairwise z-test with a Bonferroni correction to account for multiple testing and were used to

determine the significance of the contribution for each subgroup of variables.

TOAST, Trial of Org. 10172 in Acute Stroke Treatment; LAD, large artery disease; CE, cardioembolism; SVO, small vessel occlusion; OD, stroke of other determined etiology; UD, stroke of undetermined etiology; TIA, transient ischemia attack; anemia, hemoglobin <12 g/dL in females and

458 <13 g/dL in males; leukocytosis, white blood cell count >12,000/ μ L; elevated CRP, C-reactive protein

 $\geq 2 \text{ mg/dl}$; hyperhomocysteinemia, homocysteine $\geq 15 \text{ micromol/L}$; low eGFR, estimated glomerular

460 filtration rate <60 mL/min/1.73 m2; NIHSS, National Institutes of Health Stroke Scale

461

463

462

464

465

466 467

468

469

471 **Figure Legends**

472 **Figure 1**. Flowchart of patient inclusion and exclusion criteria

- 473 Figure 2. Major differences in clinical characteristics among early recurrent stroke, late
- 474 recurrent stroke, and first-ever stroke
- 475 Black (■) circular sector indicates early recurrent stroke, gray(■) indicates late recurrent
- 476 stroke, and white (\Box) indicates first-ever stroke.
- 477 These variables were selected, which had significant distribution in a bivariable analysis (P
 478 value <0.2 in Table 1).
- 479 P values were calculated using the chi-square test with Bonferroni correction to determine
- 480 the significant distribution among early recurrent stroke, late recurrent stroke, and first-ever

481 stroke. P values with asterisks (*) and black solid lines indicate statistical significance. P

482 values without asterisks and gray dotted lines indicate no statistical significance.

483

484 Figure 3. Predictive factors for each recurrent stroke by multivariable logistic regression
485 analysis

Values were expressed as odds ratios (95% CI). Polygons and lines in the plot are expressed
as odds ratios (ORs) with a 95% CI. These odds ratios were adjusted for all covariates with a
P value <0.2, as observed in the univariate analysis.

Binary logistic regression analysis was used to analyze the variables associated with total recurrent stroke. A multinomial logistic regression analysis was used to analyze the early and late recurrent stroke variables.

Values in bold font, black squares, and black lines indicate statistical significance (P<0.05).
In contrast, values in normal font, gray circles, and gray lines indicate no statistical
significance.

495 The results were adjusted for sex, body mass index, hypertension, diabetes mellitus,

- 496 congestive heart failure, TOAST, anemia, leukocytosis, CRP, $\geq 2 \text{ mg/dL}$, white matter 497 changes, and cerebral microbleeds.
- 498 TOAST, Trial of Org. 10172 in Acute Stroke Treatment; LAD, large artery disease; CE,
- 499 cardioembolism; SVO, small vessel occlusion; OD, stroke of other determined etiology; UD,
- stroke of undetermined etiology; TIA, transient ischemia attack; anemia, hemoglobin <12
- 501 g/dL in females and <13 g/dL in males; leukocytosis, white blood cell count >12,000/ μ L;
- 502 elevated CRP, C-reactive protein $\geq 2 \text{ mg/dl}$; hyperhomocysteinemia, homocysteine ≥ 15
- 503 micromol/L; low eGFR, estimated glomerular filtration rate <60 mL/min/1.73 m2; NIHSS,
- 504 National Institutes of Health Stroke Scale



University Hospitals between March 2014 and December 2021 (n = 4,508)

medRxiv preprint doi: https://doi.org/10.1101/2023.12.14.23299993; this version posted December 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission

etiology (n = 709)

- Loss of follow-up to determine stroke recurrence or others (n = 153)

Finally, 3646 patients met the study entry criteria

Recurrent stroke (n=255)

First-ever stroke (n=3,391)





(4) Diabetes mellitus

(5) Congestive heart failure

(6) TOAST classification



(10) eGFR, <60 mL/min/1.73m²





| Variables | Total recurren | | |
|--|--|-----|--|
| | Adjusted OR (95% CI) | | |
| | Fo | avo | |
| Sex, male | 2.05 (1.45-2.88) | _ | |
| Body mass index, under | 1.49 (0.82-2.70) | •- | |
| over | 1.29 (0.86-1.94) | | |
| obese | 1.02 (0.69-1.51) | - | |
| Hypertension | 1.54 (1.06-2.22) — | - | |
| Diabetes mellitus | 1.59 (1.15-2.18) - | - | |
| Cogestive heart failure | 1.03 (0.49-2.20) | | |
| TOAST, LAD | 1.14 (0.71-1.84) | | |
| CE | 1.11 (0.69-1.80) | | |
| medRxiv preprint doi: https://doi.org/10.1101/2023.12.14.23299993; this version posted December 17, 2023. The co preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to disp perpetuity. | pyright Oer fo ⁷ this 1 (0.43–1.17) | | |
| All rights reserved. No reuse allowed without permission. | 1.98 (1.04-3.78) — | | |
| TIA | 2.01 (1.18-3.43) - | | |
| Anemia | 3.96 (2.81-5.57) | | |
| Leukocytosis | 1.09 (0.66-1.78) | | |
| C-reactive protein, ≥2 mg/dL | 0.97 (0.63-1.50) | - | |
| eGFR, <60 mL/min/1.73m ² | 0.81 (0.55-1.20) - | | |
| White matter changes | 1.62 (1.08-2.44) - | _ | |
| Cerebral microbleeds | 1.88 (1.29-2.72) | | |
| | | | |

nt stroke

1

Early recurrent stroke

Adjusted OR (95% CI)





6
